AGM/EGMJun 17, 2026, 04:57 PM
Dogwood Therapeutics Stockholders Approve Share Increase, Elect Directors
AI Summary
Dogwood Therapeutics held its Annual Meeting on June 16, 2026, where stockholders approved all proposals. Key approvals included an amendment to the Certificate of Incorporation to increase authorized common and preferred stock, the election of seven directors, and the ratification of Forvis Mazars, LLP as the independent auditor for 2026. Stockholders also approved the compensation of named executive officers and opted for an annual advisory vote on executive compensation.
Key Highlights
- Stockholders approved an amendment to increase authorized common and preferred stock.
- Seven nominees were elected to serve as directors of the Company.
- Forvis Mazars, LLP was ratified as the independent auditor for fiscal year 2026 with 31,778,192 votes for.
- The amendment to increase authorized shares received 28,431,012 votes for.
- Stockholders approved an annual frequency for future advisory votes on executive compensation with 28,682,394 votes for "One Year".
- Named executive officer compensation was approved with 28,662,176 votes for.
- A quorum of 95.17% of voting power (31,791,500 shares) was present at the Annual Meeting.
Price Impact
More from DWTX
Quarterly Result50m ago
Dogwood Therapeutics Reports Q3 Net Loss of $4.88M, Down from $15.74M
Quarterly ResultAug 13, 8:56 AM
Dogwood Therapeutics Q2 Net Loss $11.5M; Halneuron® Phase 2b on track
Quarterly ResultAug 13, 8:32 AM
Dogwood Therapeutics Halneuron® Phase 2b On Track; Antiviral Deal Up To $100M